# Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
Canonical URL: https://biopharmsignal.com/news/SYBX/synlogic-announces-publication-of-preclinical-and-clinical-data-for-synb1353-as-a-potential-treatment-for-classical-homocystinuria
Ticker: SYBX
Company: Synlogic
Source: Synlogic
Published: 2024-02-02 17:00 EST
Original Source URL: https://investor.synlogictx.com
## Summary

Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study SYNB1353 was well-tolerated, with similar proportions in both the placebo and active arms reporting

## Article Body
Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study SYNB1353 was well-tolerated, with similar proportions in both the placebo and active arms reporting
## Recent Company News
- 2024-11-12 21:35 EST — [Synlogic Reports Third Quarter 2024 Financial Results](https://biopharmsignal.com/news/SYBX/synlogic-reports-third-quarter-2024-financial-results) — Source: Synlogic
- 2024-08-08 11:00 EST — [Synlogic Reports Second Quarter 2024 Financial Results](https://biopharmsignal.com/news/SYBX/synlogic-reports-second-quarter-2024-financial-results) — Source: Synlogic
- 2024-05-14 11:00 EST — [Synlogic Reports First Quarter 2024 Financial Results](https://biopharmsignal.com/news/SYBX/synlogic-reports-first-quarter-2024-financial-results) — Source: Synlogic
- 2024-03-19 11:00 EST — [Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results](https://biopharmsignal.com/news/SYBX/synlogic-reports-fourth-quarter-and-full-year-2023-financial-results) — Source: Synlogic
- 2024-02-20 17:15 EST — [Synlogic Adopts Limited Duration Stockholders Rights Plan](https://biopharmsignal.com/news/SYBX/synlogic-adopts-limited-duration-stockholders-rights-plan) — Source: Synlogic
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)